Novozymes' bioenergy suffers hard impact from reduced US consumption

The enzyme firm is confident enough to reinstate a full-year guidance but lost DKK 252 million in Q2 compared to last year. The bioenergy division is particularly hard hit.

Photo: Novozymes/PR

Log in to read our articles

Welcome to EnergyWatch. A part of our content is exclusive and reserved for our users.

Try EnergyWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles

Latest News


See all

See all